Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opioid Studies In Children Still Facing Design Challenges

Executive Summary

FDA cites Purdue and Mallinckrodt over required assessments for Dilaudid and Xartemis XR, respectively; Merck also draws letter for failing to timely submit a PREA study labeling change for the antibiotic Cubicin.

You may also be interested in...



Opioid Development Strategies In Pediatrics To Get FDA Advisory Panel Help

While FDA has long required pediatric analgesic studies, very few sponsors have managed to complete them, mainly due to enrollment challenges; advisory committees will offer recommendations on other designs that may bring a more successful result.

Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal

FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.

Pediatric Study Compliance Could Face Scrutiny In PDUFA Renewal

FDA says compliance is on par with other postmarketing requirements, but jury is still out on whether public posting of noncompliance letters has been effective tool to ensure timely trial completion.

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel